 Connection
Atsushi Oba to Deoxycytidine
This is a "connection" page, showing publications Atsushi Oba has written about Deoxycytidine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.052 |
|
|
|
-
Oba A, Ban D, Kirimura S, Akahoshi K, Mitsunori Y, Matsumura S, Ochiai T, Kudo A, Tanaka S, Minoru T. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Aug; 23(8):480-8.
Score: 0.438
-
Stoop TF, Wu YHA, Oba A, Ali M, Feld IM, Al-Musawi MH, Jain A, Saiura A, Sauvanet A, Coppola A, Javed AA, Groot Koerkamp B, Miller BN, Hashimoto D, Caputo D, Kleive D, Sereni E, Kazemier G, Belfiori G, Ishida H, van Dam JL, Dembinski J, Akahoshi K, Roberts KJ, Tanaka K, Labori KJ, Falconi M, House MG, Sugimoto M, Tanabe M, Gotohda N, Chatzizacharias N, Krohn PS, Dokmak S, Rodriguez Franco S, Hirano S, Burgdorf SK, Crippa S, Satoi S, Nguyen TK, Yamamoto T, Nakamura T, Ushida Y, Bachu V, Burns WR, Inoue Y, Takahashi Y, Aslami Z, Schulick RD, He J, Messersmith W, Besselink MG, Burkhart RA, Wilmink JW, Del Chiaro M. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study. Br J Cancer. 2025 Jul; 133(1):76-84.
Score: 0.203
-
Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, Sato T, Saiura A, Takahashi Y. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Pancreatology. 2021 Jan; 21(1):130-137.
Score: 0.149
-
Omiya K, Oba A, Sugiura K, Maekawa A, Mie T, Kobayashi K, Ono Y, Sasaki T, Ozaka M, Sasahira N, Ito H, Inoue Y, Takahashi Y. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Aug; 32(8):5411-5420.
Score: 0.051
-
Ono Y, Ito R, Kobayashi K, Oba A, Sato T, Ito H, Inoue Y, Takahashi Y. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2025 Jun; 32(6):4417-4418.
Score: 0.050
-
Ono Y, Inoue Y, Ito H, Sasaki T, Takeda T, Ozaka M, Sasahira N, Hiratsuka M, Matsueda K, Oba A, Sato T, Saiura A, Takahashi Y. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford). 2023 01; 25(1):100-108.
Score: 0.042
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. 2022 08; 29(8):5051-5052.
Score: 0.041
-
Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022 Aug; 29(8):5038-5050.
Score: 0.041
-
Inoue Y, Saiura A, Oba A, Ono Y, Mise Y, Ito H, Sasaki T, Ozaka M, Sasahira N, Takahashi Y. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021 Feb; 28(2):143-155.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|